|
|
Profile
|
Delegates :
Akito Tanaka |
|
Incorporated :
August 21 , 2014 |
Paid in Capital :
Million yen |
Employees :
2 人 |
Address :
2-2-2 Minatojima, Chuo-ku, Kobe HYOGO
〒6500046
|
TEL/FAX :
+81-78-304-3027 / |
URL：
|
Attachment :
|
Mission/Background :
KOBE Chemical Genetics was established as an academia-originated venture company by taking over the Reverse Proteomics Research Institute, which was established by 11 pharmaceutical companies under a NEDO commissioned project for the development in the Japanese pharmaceutical industry. We will contribute to drug development, including the identification of drug target proteins, by utilizing AquaFirmus, the world's best affinity resin, which was created by a former pharmaceutical company employee. |
|
Technology & Business
|
We have been contributing to drug discovery research and drug development by utilizing our drug discovery experience in pharmaceutical companies (Astellas Pharma, Kaken Pharmaceutical, Toray, Eisai, Offtex, Senju Pharmaceutical, MORESCO, etc.) and universities (Osaka University, Ehime University, etc.) through collaborative research such as identification of drug targets. AquaFirmus is affinity resin, it’s chemically stable and low non-specific binding because of hydrophilic surface & linkers. AquaFirmus2000 was successfully identified hole target protein complexes of tacrolimus (FK506) in Ag staining, which had been considered difficult to identify at once. Its’ World's first. Users have reported that the success rate of target identification is almost 99% when AquaFirmus is used.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
AquiFirmus
|
|
AquaFirmus is affinity resin, it’s chemically stable and low non-specific binding because of hydrophilic surface & linkers.
|
|
AquaFirmus2000
|
|
Optimization of linker length from AquaFirmus enabled to hold large molecular size proteins, and protein complexes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
More than 10 years have passed since the AquaFirmus was launched, and the results of its use by pharmaceutical companies, which were under confidential information, are finally being published in papers and at academic conferences. Users have reported that the success rate of target identification is almost 99% when AquaFirmus is used.
The following paper shows an example of the use of AquaFirmus: Kamiyama, et. al, Chem Biol Drug Des. 2023, 101(3): 727-739.
|
|
Alliance strategy
|
Possibility of Application: Replace of agarose or sepharose based resin
Ex; Immunoprecipitation, Tag Pulification, Ni column, Streptavidin beads, etc.
Custom synthesis.
|
|
|